Reply from the Authors
We thank Dr. Fouque for his thoughtful comments regarding the CARE study [1] . Indeed, baseline demographics showed a statistically significant difference in weight between the two treatment groups, such that the mean weight was 11% greater in the sevelamer-treated patients. However, analysis by repeated measures logistic regression showed that the difference in weight between the two groups had no effect on the primary "goalattained" outcomes for serum phosphorus or calciumphosphorus product. Moreover, three-day dietary histories were obtained on all patients at baseline, week four, and week eight to assess dietary intake of calcium and phosphorus, and there was not a statistically significant difference between the two groups at any time point during the study. Thus, we conclude that the difference in baseline weight between the two groups does not account for our finding that calcium acetate-treatment resulted in better control of serum phosphorus and calciumphosphorus product than treatment with sevelamer hydrochloride. Unfortunately, we do not have data on normalized protein catabolic rate (nPCR) in our CARE study patients.
Prestudy use of injectable vitamin D preparations was similar in the two groups; 65% of the calcium acetate group versus 60% of the sevelamer group was treated with vitamin D (P = 0.64). The study was designed such that the patient's prestudy dose of vitamin D was continued and maintained constant throughout the eight-week treatment period. Vitamin D doses were not modified in response to hypercalcemia or parathyroid hormone (PTH) levels.
Finally, the time-averaged serum calcium concentration was higher by 0.63 mg/dL in the calcium acetate group, whereas mean serum calcium levels did not change significantly from baseline values in the sevelamer group. Thus, the significant difference in calcium-phosphate product can only be explained by better control of serum phosphorus in the calcium acetate group. In this regard, because the magnitude of the change in serum phosphorus (Cavg = 1.08 mg/dL over the 8-week study) is larger than the average change in serum calcium, the attained serum phosphorus seems to be the most important variable in determining the observed difference in calciumphosphorus product between the treatment groups. Using the right MDRD equation
To the Editor: Estimating the prevalence of renal insufficiency in any patient population is of course a crucial issue. The earlier renal insufficiency is diagnosed, the best care is to be provided to the patient, especially in terms of slackening the progression of renal failure and adjusting drugs dosage when required. In their article, Garg et al [1] mentioned that they estimated the renal function of their patients using the Cockcroft-Gault and the Modification of Diet in Renal Disease Study (MDRD) formulas. They thus cited Cockcroft and Gault [2] and Levey et al [3] works in references. The authors further detailed the formulas they used in the Appendix of their article. It is important to remember that Levey et al tested in their work seven different formulas for estimating glomerular filtration rate. They concluded that among those equations, only one (equation 7) gave satisfactory results. This seventh equation is the one that should be used in other works when renal function is to be estimated with the MDRD equation. Unfortunately, the formula called MDRD formula in Garg's article is not the formula validated by Levey et al in the MDRD article.
MDRD equation for estimating glomerular filtration rate (GFR): GFR(mL/min/1. VINCENT LAUNAY-VACHER, HASSANE IZZEDINE, and GILBERT DERAY
We thank Launay-Vacher et al for their comment. Estimating glomerular filtration rate (GFR) in nursing home elderly is critical for drug dosing and end of life care, which may include dialysis. As we highlight in our paper, there are limitations to the use of both CockcroftGault and Modification of Diet in Renal Disease Study (MDRD) formulas. The best methods of estimating GFR for patient care in this population remain to be clarified. The abbreviated MDRD formula was used in our research study [1] . For transparency of reporting we included the formula in the Appendix. The abbreviated MDRD equation is used throughout Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines [2] , facilitating comparisons with our results. Levey et al suggest both MDRD equation 7 and the abbreviated MDRD formula correlate well with 125I-iothalamate GFR in middle-aged adults with kidney disease (R 2 = 0.90 and 0.89, respectively) [1] . Finally, the predictive validity of the abbreviated MDRD formula has been established-low GFR was a stronsg predictor of death and end-stage renal disease in a sample of 27,998 adults followed for 5 years [3] . Thus, we strongly disagree with Launay-Vacher et al's assertion that MDRD equation 7 was the only valid formula to be used in our analyses.
